Docoh
Loading...

BCPC Balchem

Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.

Company profile

Ticker
BCPC
Exchange
Website
CEO
Theodore Harris
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
132578432

BCPC stock data

(
)

Calendar

30 Apr 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Balchem earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Feb 21 John Y Televantos Common Stock Payment of exercise Dispose F No No 121.57 548 66.62K 28,987
11 Feb 21 William A. Backus Common Stock Payment of exercise Dispose F No No 119.13 988 117.7K 18,947
11 Feb 21 William A. Backus Common Stock Grant Aquire A No No 0 1,924 0 19,935
11 Feb 21 William A. Backus Common Stock Grant Aquire A No No 0 620 0 18,011
11 Feb 21 William A. Backus Stock Option Common Stock Grant Aquire A No No 119.13 2,300 274K 47,928
11 Feb 21 John Y Televantos Common Stock Grant Aquire A No No 0 590 0 29,535
11 Feb 21 John Y Televantos Stock Option Common Stock Grant Aquire A No No 119.13 2,124 253.03K 12,040
11 Feb 21 Theodore L Harris Common Stock Payment of exercise Dispose F No No 119.13 4,825 574.8K 62,538
11 Feb 21 Theodore L Harris Common Stock Grant Aquire A No No 0 9,840 0 67,363
11 Feb 21 Theodore L Harris Common Stock Grant Aquire A No No 0 6,060 0 57,523

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

86.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 245 251 -2.4%
Opened positions 25 38 -34.2%
Closed positions 31 32 -3.1%
Increased positions 82 79 +3.8%
Reduced positions 98 92 +6.5%
13F shares
Current Prev Q Change
Total value 3.5B 4.07B -14.0%
Total shares 27.9M 28.11M -0.8%
Total puts 400 0 NEW
Total calls 76.5K 31.7K +141.3%
Total put/call ratio 0.0
Largest owners
Shares Value Change
BLK Blackrock 5.18M $649.08M +2.9%
Vanguard 3.66M $459.31M +2.0%
Wasatch Advisors 1.53M $191.99M +18.1%
Brown Capital Management 1.17M $147.05M -15.7%
STT State Street 967.59K $121.35M +1.4%
Conestoga Capital Advisors 951.32K $119.31M +1.3%
Dimensional Fund Advisors 700.62K $87.87M -1.6%
Schroder Investment Management 692.9K $86.9M -6.3%
Geneva Capital Management 679.51K $85.22M -2.0%
APG Asset Management 620.68K $77.87M +294.4%
Largest transactions
Shares Bought/sold Change
APG Asset Management 620.68K +463.31K +294.4%
Norges Bank 0 -450.82K EXIT
Wasatch Advisors 1.53M +234.93K +18.1%
FMR 616.39K -221.57K -26.4%
Brown Capital Management 1.17M -218.91K -15.7%
BLK Blackrock 5.18M +146.43K +2.9%
Lord, Abbett & Co. 385.46K +104.79K +37.3%
Renaissance Technologies 195.5K -104.71K -34.9%
Assenagon Asset Management 99.9K +99.9K NEW
MCQEF Macquarie 416.29K -87.43K -17.4%

Financial report summary

?
Management Discussion
  • Item 7.        Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Previously, our four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with our strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, we have revised our reporting segment structure to three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019 and 2018. There was no change to the Consolidated Financial Statements as a result of the change to the reportable segments. We expect that the new reportable segment structure will provide investors greater understanding of and alignment with our strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.
  • The COVID-19 response effort has been a primary focus for us since early in the first quarter. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate. To date, all of our manufacturing sites are operating at near normal conditions enabling us to supply our customers with the important products and services they need, our
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Agency, capture, Chase, clarification, COVID, JP, legislation, merged, Morgan, passed, round, scope, SEC, slight, tailor
Removed: account, adversely, advisor, allocation, amounting, April, assigned, attrition, central, chain, characterized, Code, Commission, consulted, consumption, counteract, deductible, deemed, depending, detail, divested, dollar, elimination, emergency, ensure, entering, Euro, exemption, extreme, February, federal, globally, government, governmental, greater, heightening, home, identification, impacted, implement, implementing, improving, increasingly, indemnification, integrated, land, largely, legacy, lender, local, making, mitigate, mitigation, monetary, NV, oil, ongoing, operate, Organization, outbreak, PA, package, pattern, percent, portray, preserve, President, preventive, previously, protective, public, qualify, Reading, realignment, recent, recovery, reliably, resulted, retroactively, retrospectively, ROU, scale, school, shelter, Specifically, spread, state, stay, stringent, structure, sustainability, tangible, Targeted, technical, Trade, transparency, unpredictable, visibility, workforce